PMID- 31379147
OWN - NLM
STAT- MEDLINE
DCOM- 20200220
LR  - 20200225
IS  - 1862-1783 (Electronic)
IS  - 1673-1581 (Print)
IS  - 1673-1581 (Linking)
VI  - 20
IP  - 9
DP  - 2019 Sept.
TI  - Comparative analysis of a panel of biomarkers related to protein phosphatase 2A 
      between laryngeal squamous cell carcinoma tissues and adjacent normal tissues.
PG  - 776-780
LID - 10.1631/jzus.B1900179 [doi]
AB  - Laryngeal squamous cell carcinoma (LSCC) is the most common type of head and neck 
      squamous cell carcinoma (HNSCC) worldwide. Protein phosphatase 2A (PP2A) 
      dysfunction has been widely reported in a broad range of malignancies due to its 
      distinctive role in miscellaneous cellular processes. However, it is poorly 
      understood whether aberrant alterations of PP2A are involved in the network of 
      oncogenic events in LSCC. Here, we detected a panel of PP2A-associated proteins 
      using western blot in both laryngeal squamous cell carcinoma tissues and paired 
      adjacent normal tissues from patients (Data S1). We found that phospho-PP2A/C 
      (Y307), alpha4, cancerous inhibitor of protein phosphatase 2A (CIP2A), Akt, ezrin, 
      phospho-ezrin (T567), 14-3-3, and focal adhesion kinase (FAK) showed increased 
      expression levels in carcinoma tissues relative to normal tissues, while 
      phospho-Akt (T308) showed decreased levels. Our study, thus, provides a rationale 
      for targeting PP2A to develop novel therapies and proposes a combination of 
      interrelated biomarkers for the diagnostic evaluation and prognosis prediction in 
      LSCC.
FAU - Wang, Han-Ying
AU  - Wang HY
AD  - Department of Medical Oncology, Sir Run Run Shaw Hospital, School of Medicine, 
      Zhejiang University, Hangzhou 310016, China.
FAU - Yuan, Hui
AU  - Yuan H
AD  - Department of Otorhinolaryngology, the Second Affiliated Hospital, School of 
      Medicine, Zhejiang University, Hangzhou 310009, China.
FAU - Liu, Jing-Hui
AU  - Liu JH
AD  - Department of Toxicology and Cancer Biology, University of Kentucky, Lexington, 
      KY 40506, USA.
FAU - Wang, Bei-Lei
AU  - Wang BL
AD  - Department of Biochemistry, School of Medicine, Zhejiang University, Hangzhou 
      310058, China.
FAU - Xu, Kai-Lun
AU  - Xu KL
AD  - Cancer Institute, the Second Affiliated Hospital, School of Medicine, Zhejiang 
      University, Hangzhou 310009, China.
FAU - Huang, Pu
AU  - Huang P
AD  - Department of Biochemistry, School of Medicine, Zhejiang University, Hangzhou 
      310058, China.
FAU - Lin, Zhi-Hong
AU  - Lin ZH
AD  - Department of Otorhinolaryngology, the Second Affiliated Hospital, School of 
      Medicine, Zhejiang University, Hangzhou 310009, China.
FAU - Xu, Li-Hong
AU  - Xu LH
AD  - Department of Biochemistry, School of Medicine, Zhejiang University, Hangzhou 
      310058, China.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - China
TA  - J Zhejiang Univ Sci B
JT  - Journal of Zhejiang University. Science. B
JID - 101236535
RN  - 0 (Autoantigens)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (CIP2A protein, human)
RN  - 0 (Cytoskeletal Proteins)
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 0 (Membrane Proteins)
RN  - 0 (ezrin)
RN  - EC 2.7.10.2 (Focal Adhesion Kinase 1)
RN  - EC 2.7.10.2 (PTK2 protein, human)
RN  - EC 3.1.3.16 (Protein Phosphatase 2)
SB  - IM
MH  - Autoantigens/metabolism
MH  - Biomarkers, Tumor/*metabolism
MH  - Carcinoma, Squamous Cell/genetics/*metabolism
MH  - Case-Control Studies
MH  - Cytoskeletal Proteins/metabolism
MH  - Focal Adhesion Kinase 1/metabolism
MH  - Gene Expression Profiling
MH  - Gene Expression Regulation
MH  - *Gene Expression Regulation, Neoplastic
MH  - Humans
MH  - Intracellular Signaling Peptides and Proteins/metabolism
MH  - Laryngeal Neoplasms/genetics/*metabolism
MH  - Larynx/*metabolism
MH  - Membrane Proteins/metabolism
MH  - Phosphorylation
MH  - Protein Phosphatase 2/genetics/*metabolism
PMC - PMC6700352
OTO - NOTNLM
OT  - Laryngeal squamous cell carcinoma; Protein phosphatase 2A; Biomarker
COIS- Compliance with ethics guidelines: Han-ying WANG, Hui YUAN, Jing-hui LIU, Bei-lei 
      WANG, Kai-lun XU, Pu HUANG, Zhi-hong LIN, and Li-hong XU declare that they have 
      no conflict of interest. All procedures followed were in accordance with the 
      ethical standards of the responsible committee on human experimentation 
      (institutional and national) and with the Helsinki Declaration of 1975, as 
      revised in 2008 (5). Informed consent was obtained from all patients for being 
      included in the study.
EDAT- 2019/08/06 06:00
MHDA- 2020/02/23 06:00
PMCR- 2019/09/01
CRDT- 2019/08/06 06:00
PHST- 2019/08/06 06:00 [entrez]
PHST- 2019/08/06 06:00 [pubmed]
PHST- 2020/02/23 06:00 [medline]
PHST- 2019/09/01 00:00 [pmc-release]
AID - 10.1631/jzus.B1900179 [doi]
PST - ppublish
SO  - J Zhejiang Univ Sci B. 2019 Sept.;20(9):776-780. doi: 10.1631/jzus.B1900179.